StocktoriaPassage BIO, Inc. PASG
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-39.16
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$49.3M | -$70.4M | -$108.4M | -$138.4M | -$185.7M |
| Net income | -$45.5M | -$64.8M | -$102.1M | -$136.1M | -$185.4M |
| Operating cash flow | -$31.5M | -$48.0M | -$78.3M | -$118.2M | -$126.9M |
| Total assets | $62.3M | $102.4M | $150.5M | $243.5M | $355.1M |
| Total liabilities | $43.5M | $41.2M | $39.3M | $42.2M | $36.4M |
| Shareholders' equity | $18.8M | $61.3M | $111.3M | $201.4M | $318.7M |
| Ratios | |||||
| Return on assets | -73.1% | -63.2% | -67.8% | -55.9% | -52.2% |
| Return on equity | -242.7% | -105.7% | -91.7% | -67.6% | -58.2% |
| Current ratio | 2.07 | 4.07 | 7.22 | 10.74 | 11.02 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 133,612 | $1.0M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -39.16 (distress)
- Working capital / assets 0.396
- Retained earnings / assets -11.316
- EBIT / assets -0.792
- Equity / liabilities 0.431
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001787297 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.